Nitrous Oxide and EMOtional Cognition (NEMO)

July 28, 2025 updated by: University of Oxford

Investigating the Neuropsychological Effects of Nitrous Oxide

The goal of this study is to uncover the underlying neuropsychological mechanisms of nitrous oxide, which may be relevant to its reported antidepressant effects. In particular, the study is designed to determine whether nitrous oxide changes the way in which healthy volunteers aged 18-40 years remember negative autobiographical memories.

The main question the study aims to answer is:

• Does nitrous oxide interfere with the emotional aspects of negative autobiographical memories?

Other neuropsychological effects will also be assessed (e.g., emotional processing, emotional memory, response inhibition, and cognitive flexibility).

Researchers will compare ENTONOX (50% nitrous oxide: 50% oxygen) with medical air.

Participants will:

  • Attend three research visits (screening, inhalation, follow-up)
  • Take part in a 30 minute inhalation session of ENTONOX or medical air
  • Complete a series of cognitive tasks
  • Finish a series of self-report questionnaires

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Questions regarding the mechanisms of nitrous oxide and its effects on the brain and behaviour in the context of its reported antidepressant effects remain largely unanswered. Thus, in the present study, the investigators aim to elucidate the more general effects that nitrous oxide might have on a series of neurocognitive processes which may be relevant to the treatment of depression. Namely, the study will investigate: 1) reconsolidation of autobiographical memories, 2) measures of emotional processing and emotional memory, 3) response inhibition, 4) cognitive flexibility and 5) sleep stages.

Study Type

Interventional

Enrollment (Estimated)

88

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Aged 18-40 years
  • Good vision and hearing
  • Willing and able to give informed consent
  • Body mass index (BMI) within the range of 18-35kg/m2 (This is to ensure we exclude underweight individuals who might have more substantial reactions to the nitrous oxide).
  • Sufficiently fluent in English to understand tasks
  • Willing to avoid drinking any alcohol from 3 days prior to Visit One until the end of Visit Three
  • Willing to avoid using recreational drugs for 3 months prior to Visit One and throughout the duration of the study

Exclusion Criteria:

  • Receiving or seeking treatment for any mental health condition (covered in Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-5 (SCID) assessment in screening procedures)
  • History of any mental health condition (covered in SCID assessment in screening procedures)
  • Attention deficit hyperactivity disorder (ADHD) requiring treatment with stimulant or other centrally-acting drugs
  • A positive drug test for any of the following: amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine, marijuana, methadone, methamphetamine, methylenedioxymethamphetamine (MDMA), morphine, methaqualone, opiates, phencyclidine, propoxyphene, tricyclic antidepressants, tramadol, ketamine, oxycodone, cotinine, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), fentanyl, synthetic marijuana, 6-mono-acetyl-morphine (6-MAM).
  • Regularly drink 14 or more units of alcohol a week
  • Any eye, throat or ear surgery or a medical procedure requiring intravenous injection or line into a vein in the last 6 months
  • A head injury causing concussion or unconsciousness in the past 6 months
  • A collapsed lung or lung surgery (e.g., pneumothorax)
  • A history of cardiac arrhythmias
  • Current injuries of the face or mouth (including ulcers or dental problems)
  • Dental surgery in the past month
  • Deep diving or scuba diving (which has a risk of decompression sickness) in past month
  • Pregnancy / intention to become pregnant during the study
  • Breastfeeding during the study
  • Asthma, emphysema or any medical condition that affects the lungs or breathing
  • Diagnosed vitamin B12 deficiency
  • Any use of recreational drugs in the last three months
  • Participation in any other drug study in the last three months
  • Participation in any other study with the same tasks in the last year

OPTIONAL SLEEP STUDY ADD-ON Exclusion Criteria:

  • Unable to undergo cardiac monitoring
  • Unable to wear the sleep patch device for full monitoring period
  • Implanted neurostimulator

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ENTONOX (50% nitrous oxide:50% oxygen)
ENTONOX to be administered for 30 minutes.
30 minute inhalation using demand valve and mouthpiece
Placebo Comparator: Medical Air
Medical Air to be administered for 30 minutes.
30 minute inhalation using demand valve and mouthpiece

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in Emotional Ratings of Personal Memories (Memory Reconsolidation)
Time Frame: 2 days before and 1 day after treatment
Negative/positive valence ratings associated with personal memories. A series of positive and negative adjectives will be presented to participants and they will have to rate on a scale of 1(not at all) to 10 (extremely) to what extent these words apply to how they feel when recalling the memory.
2 days before and 1 day after treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Performance on Emotional Processing Tasks
Time Frame: Immediately before and after treatment and 1 day after treatment
Performance on the Emotional Testing Battery (ETB), which contains an emotional word categorisation task, an emotional facial recognition task, and two emotional memory tasks.
Immediately before and after treatment and 1 day after treatment
Performance on Cognitive Flexibility Task
Time Frame: 1 day after treatment
Performance on a probabilistic reversal learning task in which participants have to learn which strategy on a computer-task leads to a reward.
1 day after treatment
Performance on Response Inhibition Task
Time Frame: 1 day after treatment
Performance on an emotional go/no-go task in which participants have to inhibit their responses to certain stimuli based on rules given at the start of each block of the task.
1 day after treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 10, 2024

Primary Completion (Estimated)

August 15, 2025

Study Completion (Estimated)

October 1, 2025

Study Registration Dates

First Submitted

July 19, 2024

First Submitted That Met QC Criteria

August 13, 2024

First Posted (Actual)

August 16, 2024

Study Record Updates

Last Update Posted (Actual)

July 31, 2025

Last Update Submitted That Met QC Criteria

July 28, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on Entonox

Subscribe